Wells Fargo’s Virax Biolabs VRAX Stock Holding History

Wells Fargo’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$116	–	7095
2024 Q2	$116	Hold	4	–	–	﹤0.01%	6237
2024 Q1	$72	Sell	4 -4	-50%	-$93	﹤0.01%	6737
2023 Q4	$292	Hold	8	–	–	﹤0.01%	6510
2023 Q3	$650	Hold	8	–	–	﹤0.01%	6303
2023 Q2	$780	Buy	+8	New	+$880	﹤0.01%	6385

Other funds holding VRAX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Headlands Technologies Chicago, Illinois $878M AUM 44.8% 1-Year Est. Return

Wells Fargo's VRAX Position: Q3 2024 in Review

Wells Fargo sold out of Virax Biolabs (VRAX) in Q3 2024, closing a stake of 4 shares — an estimated $116 sold.

Wells Fargo first reported a position in VRAX in Q2 2023 and held it in 5 quarters. The position peaked at $780 in Q2 2023. 5 funds tracked by Wall St. Rank hold VRAX as of Q3 2024.

Wells Fargo reported no remaining Virax Biolabs position as of Q3 2024 after selling out during the quarter.
Wells Fargo sold 4 Virax Biolabs shares in Q3 2024, an estimated $116.
Wells Fargo first reported a position in Virax Biolabs in Q2 2023 and held it in 5 quarters.
Wells Fargo's Virax Biolabs position peaked at $780 in Q2 2023.
5 funds tracked by Wall St. Rank held Virax Biolabs as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.